Clinical Trial Update: A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study of BDC-1001 alone and in combination with nivolumab in advanced HER2-expressing solid tumors; the trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Endometrial Cancer
• Gastric Cancer

Drugs mentioned

• BDC-1001
• nivolumab (nivolumab)

Snippet

Sponsor: Bolt Biotherapeutics, Inc. | Conditions: HER2-positive Solid Tumors, HER2-positive Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED